SAROGLITAZAR



NAME OF DRUG : SAROGLITAZAR

ALSO KNOWN AS : SAROGLITAZAR

LABORATORY : ZYDUS

STATUS AND ADVANCEMENT

Type of drug : dual PPAR-α γ agonist

Clinical trials advancement : Initiating Phase 2b

Estimated time to market : 103 months.

LABORATORY ABSTRACT ON THE DRUG

LipaglynTM (Saroglitazar) is currently approved in India as a prescription medicine for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. The recommended dose of LipaglynTM is 4 mg once-a-day. LipaglynTM (Saroglitazar) was launched in India during September 2013. Since then more than 300,000 patients have been treated with LipaglynTM in India to date and data has been presented at several scientific and medical conferences. Additional Phase III trials are ongoing in non- alcoholic steatohepatitis (NASH), lipodystrophy, severe hypertriglyceridemia and few additional indications. A post-marketing Phase-IV study is currently underway in patients suffering from hypertriglyceridemia in India.

RECENT NEWS ON SAROGLITAZAR

SOME PUBLICATIONS RELATED WITH SAROGLITAZAR

January 2015 : The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SAROGLITAZAR


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE